KALV Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

8 Analyst Rating

Wall Street analysts forecast KALV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KALV is 31.14 USD with a low forecast of 27.00 USD and a high forecast of 39.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

8 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

27.00

Averages

31.14

High

39.00

Current: 0.000

Low

27.00

Averages

31.14

High

39.00

Citizens

Outperform

maintain

$28 -> $29

2026-01-09

New

Reason

Citizens

Price Target

$28 -> $29

2026-01-09

New

maintain

Outperform

Reason

Citizens raised the firm's price target on KalVista to $29 from $28 and keeps an Outperform rating on the shares. Ekterly posted a strong Q4 launch with $35M in revenue, well above expectations, driven by robust start forms and refills, though some holiday-related seasonality was evident, the analyst tells investors in a research note. While early performance implies an annualized run-rate above 2026 consensus, confirmation of sustained demand will hinge on a rebound in start forms in 1Q26, with refills expected to remain the primary revenue driver, the firm says.

H.C. Wainwright

Andrew Fein

Buy

maintain

$27 -> $37

2026-01-09

New

Reason

H.C. Wainwright

Andrew Fein

Price Target

$27 -> $37

2026-01-09

New

maintain

Buy

Reason

H.C. Wainwright analyst Andrew Fein raised the firm's price target on KalVista to $37 from $27 and keeps a Buy rating on the shares. The firm believes the announced fiscal 2025 Ekterly revenue support the thesis that an oral therapy will become the on-demand therapy of choice for hereditary angioedema.

Needham

Buy

maintain

$28 -> $32

2026-01-06

New

Reason

Needham

Price Target

$28 -> $32

2026-01-06

New

maintain

Buy

Reason

Needham raised the firm's price target on KalVista (KALV) to $32 from $28 and keeps a Buy rating on the shares. KalVista is being added to Needham's Conviction List, replacing Liquidia (LQDA), given Yutepria's growing uptake across pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. KalVista represents a compelling 2026-story given an attractive valuation that doesn't yet reflect Ekterly's initial launch success, the analyst tells investors in a research note.

Oppenheimer

Outperform

maintain

$44 -> $50

2025-12-04

Reason

Oppenheimer

Price Target

$44 -> $50

2025-12-04

maintain

Outperform

Reason

Oppenheimer raised the firm's price target on Pharvaris (PHVS) to $50 from $44 and keeps an Outperform rating on the shares. The firm notes the company reported positive top-line results for the pivotal RAPIDe-3, study of deucrictibant in the on-demand setting, hitting statistical significance across all primary and secondary endpoints. This result is a clear win for Pharvaris in the on-demand setting where it will compete with Kalvista's (KALV) recently launched Ekterly, with positive read-across to deucrictibant in the larger prophylactic setting, with those pivotal results anticipated in the second half of 2026.

Citizens JMP

Outperform

maintain

$29 -> $28

2025-11-11

Reason

Citizens JMP

Price Target

$29 -> $28

2025-11-11

maintain

Outperform

Reason

Citizens JMP lowered the firm's price target on KalVista to $28 from $29 and keeps an Outperform rating on the shares. Early demand for Ekterly looks strong, with 937 start forms as of the end of October, covering roughly 8% of the diagnosed U.S. hereditary angioedema population, the analyst tells investors in a research note. The 937 start forms represent about $31M in potential revenue, the firm notes, adding that the early demand is "promising."

BofA

Buy

downgrade

$36 -> $29

2025-10-22

Reason

BofA

Price Target

$36 -> $29

2025-10-22

downgrade

Buy

Reason

BofA lowered the firm's price target on KalVista to $29 from $36 and keeps a Buy rating on the shares. The firm adjusted targets among its small-to-mid cap biotech coverage as part of a Q3 earnings preview for the group.

Valuation Metrics

The current forward P/E ratio for Kalvista Pharmaceuticals Inc (KALV.O) is -4.13, compared to its 5-year average forward P/E of -4.01. For a more detailed relative valuation and DCF analysis to assess Kalvista Pharmaceuticals Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-4.01

Current PE

-4.13

Overvalued PE

-1.91

Undervalued PE

-6.12

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-0.54

Current EV/EBITDA

-3.83

Overvalued EV/EBITDA

0.56

Undervalued EV/EBITDA

-1.65

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

163.65

Current PS

11.93

Overvalued PS

692.74

Undervalued PS

-365.45

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds areSelling! The selling amount has increased 7382.63% over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

KALV News & Events

Events Timeline

No data

News

6.0

01-09Benzinga

Needham Raises Kalvista Price Target to $35

5.0

01-09Benzinga

KalVista Launches EKTERLY, Achieves $35M in First-Year Revenue

9.5

01-09Benzinga

Greenbrier Companies Inc Beats Q1 Earnings Estimates with $1.14 EPS and $706.1M Sales

People Also Watch

Frequently Asked Questions

What is Kalvista Pharmaceuticals Inc (KALV) stock price today?

The current price of KALV is 16.8 USD — it has increased 6.19 % in the last trading day.

What is Kalvista Pharmaceuticals Inc (KALV)'s business?

KalVista Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drug therapies for diseases with significant unmet need. Its product candidate is sebetralstat, an inhibitor of plasma kallikrein being developed for hereditary angioedema (HAE). Sebetralstat is designed to offer people living with HAE a medication that can be taken as a discreet oral dose to readily treat HAE attacks on-demand, including at the earliest signs before the attack fully develops. Sebetralstat works by targeting the kallikrein-kinin system (KKS) cascade, selectively inhibiting plasma kallikrein and its uncontrolled activity that drives HAE attacks. The Company is also designing an oral Factor XIIa inhibitor for HAE prophylaxis, positioning KalVista to address the full spectrum of HAE disease management. Factor XIIa inhibitor program is developed to address other therapeutic areas, including inflammation and thrombosis.

What is the price predicton of KALV Stock?

What is Kalvista Pharmaceuticals Inc (KALV)'s revenue for the last quarter?

Kalvista Pharmaceuticals Inc revenue for the last quarter amounts to 13.69M USD, decreased % YoY.

What is Kalvista Pharmaceuticals Inc (KALV)'s earnings per share (EPS) for the last quarter?

Kalvista Pharmaceuticals Inc. EPS for the last quarter amounts to -0.92 USD, increased 9.52 % YoY.

What changes have occurred in the market's expectations for Kalvista Pharmaceuticals Inc (KALV)'s fundamentals?

The market is revising Upward the revenue expectations for KalVista Pharmaceuticals, Inc. (KALV) for FY2025, with the revenue forecasts being adjusted by 121.65% over the past three months. During the same period, the stock price has changed by 42.25%.

How many employees does Kalvista Pharmaceuticals Inc (KALV). have?

Kalvista Pharmaceuticals Inc (KALV) has 270 emplpoyees as of January 10 2026.

What is Kalvista Pharmaceuticals Inc (KALV) market cap?

Today KALV has the market capitalization of 849.18M USD.